Office of Research Business Development and Industry Translation (ORBIT)

Our dedication to bringing innovations to the marketplace is deeply rooted in our scientific community’s translational culture and world-class expertise in clinical decision making and health care IT.  In 2010, Richard H. Karas, MD, PhD, Chief Science Officer at Tufts Medical Center, realized his longstanding vision of commercializing the many research breakthroughs at our institution by founding ORBIT (Office of Business Development and Industry Translation).

To lead ORBIT, Dr. Karas enlisted Nancy Wetherbee, a veteran biotech and pharmaceutical executive. Shortly thereafter, Dr. Karas and Nancy Wetherbee created the Innovation and Venture Capital and Entrepreneurism Steering Committee (INVEST) in 2012, a board of external venture capital, private investors and entrepreneurs who advise ORBIT on bridging our most commercially valuable technologies into commercially attractive healthcare investment opportunities.

Tufts Medical Center held its inaugural INNOVATION Day in the fall of 2012, featuring investor-selected innovations.

View the videos below to learn about research that one day soon may save or improve people’s lives.

Our Research Breakthroughs Offer Exceptional Business Opportunities for Industry

ORBIT creates new business opportunities by forging partnerships with industry and the investment community to bring to market commercially relevant innovations from Tufts Medical Center. Since 1997, our translationally focused medical center, in collaboration with our entrepreneurial business partners and investors, has launched medical startups focusing on advancements in fetal monitoring, stroke detection and cancer therapy, to name but a few.

At ORBIT, our veteran industry business development team ensures expedited response necessary to meet industry timelines. We serve as your portal to pipeline growth by identifying strategic opportunities matching industry pipeline needs with basic and clinical research that exhibits extraordinary potential for translation into profitable therapies, devices, diagnostics or healthcare IT technologies.

Our research portfolio offers a wealth of high value prospects for partnerships, from late stage inventions that can be rapidly developed into valuable products, as well as promising innovations in earlier stages of development that are ready to partner for focused , 12-to-18-month proof of concept studies.

We offer a wide range of commercially relevant opportunities and services:

Our Commercially Relevant Innovations Offer Exceptional Opportunities for Investors

Tufts Medical Center’s INVEST portfolio is comprised of ten technologies, including biopharmaceutical, medical device, diagnostic and healthcare IT opportunities from concept stage through revenue-generating phase.  INVEST portfolio technologies have been vetted by an outside advisory board of seasoned investors and serial entrepreneurs.

For Strategic Industry Partnering or Health Care Investment Opportunities

To learn more about partnering or investing with us:
Call us today at 617-636-6182 or email Nancy Wetherbee, Director, Office of Research Business Development and Industry Translation.

Additionally, we invite you to explore several of our latest discoveries by viewing presentations from our invitation-only industry and investor INNOVATION Day.